MedTrace Logo

Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

NCT06121232 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-17

No results posted yet for this study

Summary

To learn if a process called neuromodulation can help to improve pain due to CIP

Conditions

  • Neuropathy;Peripheral

Interventions

DEVICE

Abbott® DRG / Abbott®/Medtronic® SCS

Participants will receive 1 of 2 neuromodulation procedures based on if participants are expected to have an MRI in the near future.

OTHER

Control Group

Participants will not receive any intervention

Sponsors & Collaborators

  • Foundation for Anesthesia Education and Research

    collaborator OTHER

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Saba Javed, M D · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-02
Primary Completion
2026-04-01
Completion
2026-04-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06121232 on ClinicalTrials.gov